Apinya Jusakul

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9692001/publications.pdf

Version: 2024-02-01

27 papers	1,713 citations	623734 14 h-index	526287 27 g-index
28 all docs	28 docs citations	28 times ranked	3185 citing authors

#	Article	IF	Citations
1	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discovery, 2017, 7, 1116-1135.	9.4	637
2	Exome sequencing identifies distinct mutational patterns in liver flukeâ€“related and non-infection-related bile duct cancers. Nature Genetics, 2013, 45, 1474-1478.	21.4	426
3	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine, 2016, 8, 195-202.	6.1	94
4	Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. Genome Research, 2017, 27, 1475-1486.	5.5	90
5	Mechanisms of oxysterol-induced carcinogenesis. Lipids in Health and Disease, 2011, 10, 44.	3.0	69
6	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	9.4	48
7	Genetics of Opisthorchis viverrini-related cholangiocarcinoma. Current Opinion in Gastroenterology, 2015, 31, 258-263.	2.3	45
8	Liver fluke-induced hepatic oxysterols stimulate DNA damage and apoptosis in cultured human cholangiocytes. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012, 731, 48-57.	1.0	36
9	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. JCO Global Oncology, 2020, 6, 628-638.	1.8	35
10	Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 233-244.	2.4	34
11	Expression of oxysterol binding protein isoforms in opisthorchiasis-associated cholangiocarcinoma: A potential molecular marker for tumor metastasis. Parasitology International, 2012, 61, 136-139.	1.3	28
12	Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand. Tumor Biology, 2017, 39, 101042831772592.	1.8	27
13	Anti-apoptotic phenotypes of cholestan-3Î²,5Î±,6Î²-triol-resistant human cholangiocytes: Characteristics contributing to the genesis of cholangiocarcinoma. Journal of Steroid Biochemistry and Molecular Biology, 2013, 138, 368-375.	2.5	20
14	A combination of monosodium glutamate and high-fat and high-fructose diets increases the risk of kidney injury, gut dysbiosis and host-microbial co-metabolism. PLoS ONE, 2020, 15, e0231237.	2.5	18
15	Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. Life Sciences, 2022, 296, 120427.	4.3	14
16	Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma. Asian Pacific Journal of Cancer Prevention, 2012, 13 Suppl, 77-82.	1.2	13
17	Establishment of a Potential Serum Biomarker Panel for the Diagnosis and Prognosis of Cholangiocarcinoma Using Decision Tree Algorithms. Diagnostics, 2021, 11, 589.	2.6	10
18	Association of CYP39A1, RUNX2 and Oxidized Alpha-1 Antitrypsin Expression in Relation to Cholangiocarcinoma Progression. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10187-10192.	1.2	10

#	Article	IF	Citations
19	Circulating TGF-Î²1 as the potential epithelial mesenchymal transition-biomarker for diagnosis of cholangiocarcinoma. Journal of Gastrointestinal Oncology, 2020, 11, 304-318.	1.4	9
20	Vitamin C supplementation reduces expression of circulating miR-451a in subjects with poorly controlled type 2 diabetes mellitus and high oxidative stress. PeerJ, 2021, 9, e10776.	2.0	9
21	ARID1A alterations and their clinical significance in cholangiocarcinoma. PeerJ, 2020, 8, e10464.	2.0	9
22	Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma. Diagnostics, 2021, 11, 999.	2.6	8
23	Current omics-based biomarkers for cholangiocarcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 997-1005.	3.1	7
24	Serum coiledâ€'coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma. Oncology Letters, 2020, 19, 930-942.	1.8	5
25	Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma. PeerJ, 2022, 10, e12750.	2.0	5
26	Promoter hypermethylation of early B cell factor 1 (EBF1) is associated with cholangiocarcinoma progression. Journal of Cancer, 2021, 12, 2673-2686.	2.5	4
27	Serum Angiopoietin-Like Protein 4: A Potential Prognostic Biomarker for Prediction of Vascular Invasion and Lymph Node Metastasis in Cholangiocarcinoma Patients. Frontiers in Public Health, 2022, 10, 836985.	2.7	2